Suven Life Sciences Ltd, a Hyderabad based biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, has secured four product patents, two from China (ZL 200580040477.8 and ZL 200780045451.5) and two from Korea (1097415 and 1103023) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2025 and 2027.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and schizophrenia.
With these new patents, Suven has a total of five granted patents from China and seven granted patents from Korea. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase I or phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorder with high unmet medical need and an estimated $30 billion market potential globally,” said Venkat Jasti, CEO of Suven.